Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.43 |
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373578 | 0.80 | CA1 (0.66) | CA1CA2CA9KDM4EALDH1A1 | |
| SCHEMBL8548169 | 0.80 | CA2 (0.43) | CA1CA2CA9CA12 | |
| SCHEMBL10627723 | 0.78 | ESR1 (0.50) | CA1CA2CA9KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL28342908 | 0.78 | CA1 (0.63) | CA1CA2CA9KDM4EALDH1A1 | |
| Phosphine SCHEMBL29064577 | 0.78 | CA1 (0.63) | CA1CA2CA9KDM4EALDH1A1 | |
| SCHEMBL9002486 | 0.77 | RECQL (0.48) | CA1CA2CA9ALDH1A1CYP3A4 | |
| Hydrazine SCHEMBL1308719 | 0.77 | CA2 (0.67) | CA1CA2CA9KDM4EALDH1A1 | |
| SCHEMBL30669408 | 0.77 | CYP19A1 (0.42) | CA1CA2CA9MAPTCA12 | |
| SCHEMBL4611003 | 0.76 | CA2 (0.35) | CA2ALDH1A1LMNACYP3A4GAA | |
| Sulfur Dioxide SCHEMBL27681092 | 0.76 | CA2 (0.59) | CA1CA2CA9KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1975205-B1 | TRISAZO COMPOUND, INK COMPOSITION, RECORDING METHOD AND COLORED MATTER | NIPPON KAYAKU KK (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8167991-B2 | Trisazo compound, ink composition, recording method, and colored article | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20090062545-A1 | Trisazo Compound, Ink Composition, Recording Method, and Colored Article | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1975205-A1 | TRISAZO COMPOUND, INK COMPOSITION, RECORDING METHOD AND COLORED MATTER | Nipponkayaku Kabushikikaisha (JP) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062545-A1 | Trisazo Compound, Ink Composition, Recording Method, and Colored Article | JAK1, TMT1A, CDK1 | CA1 272/4885CA2 186/4885CA9 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.